Physician profile
Michael Nuzzo
NPI 1265583587
$5,831.67
in general payments reported to CMS, 2019-2025
10 companies · $20.72 in 2025
The $20.72 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $42.59 · 2021: $2,211 · 2022: $2,000 · 2023: $475 · 2025: $20.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,153.83 | 2022-2023 | |
| Stryker Corporation | $1,768.91 | 2019-2023 | Salvation, Mako, Insignia |
| Sequoia Surgical, INC. | $1,656.81 | 2019-2021 | |
| Cornerstone Medical Associates, INC. | $113.62 | 2023 | |
| Sanofi-Aventis U.S. LLC | $43.17 | 2019 | |
| Pacira Therapeutics, INC. | $37.74 | 2019 | |
| Vericel Corporation | $24.76 | 2019 | |
| Bioventus LLC | $20.72 | 2025 | Gelsyn-3 |
| Zyla Life Sciences, INC. | $12.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$920,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Nuzzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.